| HOME >> MEDICINE >> TECHNOLOGY |
6.4 Genericization and Emerging Business Models Driving a Need for Novel Drug Delivery Methods 41
7 Nanotechnology in Drug Delivery – Regulatory Landscape 42
7.1 Introduction 42
7.2 Europe 44
7.2.1 REACH Regulation 44
7.2.2 European Medicines Agency 46
7.3 The US 46
7.3.1 Environment Protection Agency 46
7.3.2 Food and Drug Administration 47
7.3.3 National Institute of Occupational Safety and Health 47
7.4 Japan 48
8 Nanotechnology in Drug Delivery – Pipeline Analysis 49
8.1 Overview 49
8.1.1 Pipeline Analysis by Phase 50
9 Nanotechnology in Drug Delivery – Strategic Consolidations 55
9.1 Overview 55
9.2 Mergers and Acquisitions 55
9.2.1 Mergers and Acquisitions by Geography 55
9.2.2 Mergers and Acquisitions by Deal value 56
9.2.3 Mergers and Acquisition Analysis by Deal Type 57
9.3 Summary of Major M&A Deals 58
9.3.1 AstraZeneca Acquires MedImmune 58
9.3.2 Pfizer Completes Acquisition of Wyeth 58
9.3.3 Celgene Announces To Acquire Abraxis BioScience 58
9.3.4 Amgen Acquires Abgenix 59
9.3.5 Teva Pharmaceutical Acquires Ivax 59
9.4 Licensing Agreement 60
9.4.1 Deals by Year of Consolidations 60
9.4.2 Deals by Geography 61
9.4.3 Deals by Deal value 62
9.5 Summary of Major M&A Deals 62
9.5.1 AstraZeneca Enters Into Collaboration and Licensing Agreement with Targacept 62
9.5.2 AstraZeneca Enters into Licensing Agreement with Rigel Pharmaceuticals 63
9.5.3 Isis Pharmaceuticals Enters Into Licensing Agreement with Genzyme 63
9.5.4 Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca 63
9.5.5 Abraxis Enters Into License Agreement With ProMetic Life Sciences 64
10 Nanotechnology in Drug Delivery – Fut
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |